Community based integrated intervention for prevention and management of chronic obstructive pulmonary disease (COPD) in Guangdong, China: Cluster randomised controlled trial

BMJ (Online)

Volumn 341, Issue 7784, 2010, Pages 1203-

  Zhou, Yumin ^a   Hu, Guoping ^a   Wang, Dali ^b   Wang, Shaoyi ^c   Wang, Yujun ^c   Liu, Zhigang ^c   Hu, Jinxin ^a   Shi, Zhe ^a   Peng, Gongyong ^a   Liu, Shengming ^a,d   Lu, Jiachun ^e   Zheng, Jingping ^a   Wang, Jian ^a,f   Zhong, Nanshan ^a   Ran, Pixin ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Second Hospital of Liwan District of Guangzhou   (China)

^c Guangzhou Environmental Monitoring Center   (China)

^d JINAN UNIVERSITY   (China)

^e GUANGZHOU MEDICAL UNIVERSITY   (China)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALBUTAMOL;

ADULT; AGED; AIR QUALITY; ARTICLE; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATION; FORCED VITAL CAPACITY; HEALTH EDUCATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING CESSATION;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; AIR POLLUTANTS; AIR POLLUTION; BRONCHODILATOR AGENTS; CHINA; CLUSTER ANALYSIS; COMMUNITY HEALTH SERVICES; EARLY DIAGNOSIS; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH EDUCATION; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; SULFUR DIOXIDE; VITAL CAPACITY;

EID: 78649893510     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6387     Document Type: Article

References (33)

1. Sin DD, Stafinski The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med 2002;165:704-7.
2. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-3.
3. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the burden of obstructive lung disease study): a population-based prevalence study. Lancet 2007;370:741-50. (Pubitemid 47321907)
4. Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China - a large populationbased spirometry based cross-sectional survey. Am J Respir Crit Care Med 2007;176:753-60.
5. Chan-Yeung M, Aït-Khaled N, White N, Ip MS, Tan WC. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 2004;8:2-14. (Pubitemid 38120700)
6. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161:381-90.
7. Tabak C, Smit HA. Diet and chronic obstructive pulmonary disease: independent beneficial effects of fruits, whole grains, and alcohol (the MORGEN study) Clin Exp Allergy 2001;31:747-55. (Pubitemid 32823819)
8. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
9. Troosters T, Casaburi R, Gosselink R, Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38. (Pubitemid 40923311)
10. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
11. Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, et al. COPD in Chinese nonsmokers. Eur Respir J 2009;33:509-18.
12. Gu D, Wu X, Reynolds K, Duan X, Xin X, Reynolds RF, et al. Cigarette smoking and exposure to environmental tobacco smoke in China: the international collaborative study of cardiovascular disease in Asia. Am J Public Health 2004;94:1972-6.
13. Yang G, Fan L, Tan J, Qi G, Zhang Y, Samet JM, et al. Smoking in China, finding of the 1996 national prevalence of survey. JAMA 1999;282:1247-53.
14. American Thoracic Society. Standardization of spirometry. 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
15. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
16. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55
17. Zheng J, Zhong N. Normative values for pulmonary function testing in Chinese adults. Chin Med J (Engl) 2002;115:50-4. (Pubitemid 34130435)
18. Donner A, Klar N. Design and analysis of cluster randomization trials in health research. Oxford University Press, 2000.
19. Browner WS, DuChene AG, Hulley SB. Effects of the Multiple Risk Factor Intervention Trial smoking cessation program on pulmonary function - a randomized controlled trial. West J Med 1992;157:534-8
20. 1 the lung health study. JAMA 1994;272:1497-505.
21. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23:464-76.
22. 1 decline in a cross-sectional and longitudinal study of a large cohort of Japanese males. Respirology 2005;10:464-9.
23. Tager I, Segal MR, Speizer FE, Weiss ST. The natural history of forced expiratory volumes - Effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis 1988;138:837-49.
24. Gauderman WJ, Avol E, Gilliland F, Vora H, Thomas D, Berhane K, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med2004;351:1057-67. [Erratumin N Engl J Med 2005;352:1276.]
25. Garcia-Aymerich J, Hernandez C, Alonso A, Casas A, Rodriguez-Roisin R, Anto JM, et al. Effects of an integrated care intervention on risk factors of COPD readmission. Respir Med 2007;101:1462-9.
26. Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernadez C, Alonso A, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006;28:123-30.
27. 1 decline in current smokers, but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64.
28. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized controlled trial. Lancet 2009;374:1171-8.
29. Celli B, Thomas N, Anderson J, Ferguson JT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:332-8.
30. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008;63:768-74.
31. Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not <70%. Chest 2007;131:349-55. (Pubitemid 46280391)
32. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miler JR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces themisclassification of airway obstruction. Thorax 2008;63:1046-51
33. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875-81.